Evidence map›Paper›PMID 37680625›Full record

ArticleFrontiers in immunology2023

Post-COVID symptoms are associated with endotypes reflecting poor inflammatory and hemostatic modulation.

Andy Yi An, Arjun Baghela, Peter G Y Zhang, Travis M Blimkie, Jeff Gauthier, Daniel Elias Kaufmann, Erica Acton, Amy H Y Lee, Roger C Levesque, Robert E W Hancock

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Barriers to Long COVID Care in the U.S.: An Application of Levesque et al.'s Access Framework.Health care analysis : HCA : journal of health philosophy and policy · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Andy Yi AnCentre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada.
Arjun BaghelaCentre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada.
Peter G Y ZhangCentre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada.
Travis M BlimkieCentre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada.
Jeff GauthierDépartement de microbiologie-infectiologie et d'immunologie, Université de Laval, Laval, QC, Canada.
Daniel Elias KaufmannDepartment of Medicine, Université de Montréal, Montréal, QC, Canada.
Erica ActonDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Amy H Y LeeDepartment of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada.
Roger C LevesqueDépartement de microbiologie-infectiologie et d'immunologie, Université de Laval, Laval, QC, Canada.
Robert E W HancockCentre for Microbial Diseases and Immunity Research, University of British Columbia, Vancouver, BC, Canada.
University of British Columbia · CASimon Fraser University · CAUniversité Laval · CAUniversité de Montréal · CA

Funding

CIHR FDN-154287
6 · The paper itself

Abstract

Introduction: Persistent symptoms after COVID-19 infection ("long COVID") negatively affects almost half of COVID-19 survivors. Despite its prevalence, its pathophysiology is poorly understood, with multiple host systems likely affected. Here, we followed patients from hospital to discharge and used a systems-biology approach to identify mechanisms of long COVID. Methods: RNA-seq was performed on whole blood collected early in hospital and 4-12 weeks after discharge from 24 adult COVID-19 patients (10 reported post-COVID symptoms after discharge). Differential gene expression analysis, pathway enrichment, and machine learning methods were used to identify underlying mechanisms for post-COVID symptom development. Results: Compared to patients with post-COVID symptoms, patients without post-COVID symptoms had larger temporal gene expression changes associated with downregulation of inflammatory and coagulation genes over time. Patients could also be separated into three patient endotypes with differing mechanistic trajectories, which was validated in another published patient cohort. The "Resolved" endotype (lowest rate of post-COVID symptoms) had robust inflammatory and hemostatic responses in hospital that resolved after discharge. Conversely, the inflammatory/hemostatic responses of "Suppressive" and "Unresolved" endotypes (higher rates of patients with post-COVID symptoms) were persistently dampened and activated, respectively. These endotypes were accurately defined by specific blood gene expression signatures (6-7 genes) for potential clinical stratification. Discussion: This study allowed analysis of long COVID whole blood transcriptomics trajectories while accounting for the issue of patient heterogeneity. Two of the three identified and externally validated endotypes ("Unresolved" and "Suppressive") were associated with higher rates of post-COVID symptoms and either persistently activated or suppressed inflammation and coagulation processes. Gene biomarkers in blood could potentially be used clinically to stratify patients into different endotypes, paving the way for personalized long COVID treatment.

Indexed as

Body FluidsCOVID-19HemostaticsAdultBlood CoagulationDown-RegulationHumansPost-Acute COVID-19 SyndromeHemostaticsCOVID-19endotypesgene expressionlong COVIDpersonalized medicine

Identifiers

PMID37680625
PMCPMC10482103
OpenAlexW4386100414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.